Filing search / Incannex Healthcare Limited / "Opioid"

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

market size US$28.9 billion in 2024 with estimated 9.2% CAGR) and a candidate for the treatment of opioid addiction (estimated global market size

S-1/A

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

initial focus will be on opioid addiction, smoking cessation, cannabis use disorder, vitiligo, atopic dermatitis and psoriasis. We expect to pursue FDA … . Our initial focus will be on opioid addiction, smoking cessation, cannabis use disorder, vitiligo, atopic dermatitis and psoriasis. We are pursuing

S-1

IXHL Incannex Healthcare Limited

3 Jul 24

IPO registration

6:29am

will be on opioid addiction, smoking cessation, cannabis use disorder, vitiligo, atopic dermatitis and psoriasis. We expect to pursue FDA registration … of APIRx we are also developing cannabinoid products to target additional indications. Our initial focus will be on opioid addiction, smoking cessation

8-K

IXHL Incannex Healthcare Limited

7 May 24

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

8:30am

with the FDA for CannQuit-O for treatment of opioid use disorder. Further information is included in the press release attached as Exhibit 99.1 hereto

8-K

EX-99.1

IXHL Incannex Healthcare Limited

7 May 24

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

8:30am

for treatment of opioid use disorder MELBOURNE, Australia and NEW YORK, May 7, 2024: Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company … Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for treatment of Opioid Use Disorder (OUD

6-K

EX-99.1

wcf3zo878y 28s

1 Sep 23

Report of Foreign Private Issuer

12:00am

6-K

EX-99.1

z89nfjihdtc89

27 Jul 23

Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement

8:47pm

6-K

EX-99.1

xzs hpwsd5cl

30 May 23

Report of Foreign Private Issuer

8:02am

6-K

EX-99.1

2ow2qozbpy i9

13 Apr 23

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

9:23pm

6-K

EX-99.1

phvx 19885tlh

25 Nov 22

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

6:08am

20-F

zkom3ig5c1a8z k2jce8

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

7h8e74

19 Sep 22

Report of Foreign Private Issuer

9:38pm

6-K

EX-99.1

l645hf

9 Aug 22

Report of Foreign Private Issuer

6:01am

6-K

EX-99.1

zzoela4ycm rg9jkri4

4 Aug 22

Report of Foreign Private Issuer

8:32pm

6-K

EX-99.1

1gbdjdqjnp82 8qtm

28 Jul 22

Incannex Healthcare Quarterly Activities Report and Appendix 4C

2:35pm

6-K

EX-99.3

3j3up9psuppts8ghern

12 May 22

Report of Foreign Private Issuer

9:25am

6-K

EX-99.1

mgb0mspqed8u

28 Apr 22

Quarterly Activities Report and Appendix 4C Cash Flow Statement

6:40am

6-K

EX-99.1

72fdeoidzwu

4 Apr 22

Incannex to Acquire APIRx Pharmaceuticals USA, LLC

6:07am